The Pennsylvania Opioid Data Dashboard provides data behind Pennsylvania's response to the opioid crisis.

The Wolf Administration is helping to rescue opioid use disorder patients and children born suffering from withdrawal symptoms by enhancing the state's response to the opioid epidemic.

The Wolf Administration is increasing access to treatment for people suffering with opioid use disorder. This tells the story of treatment within the state of Pennsylvania.

The Wolf Administration is working to reduce over-prescribing of opioids through use of the the Prescription Drug Monitoring Program and prescribing guidelines.

This dataset contains summary information on opioid drug seizures and arrests made by Pennsylvania State Police (PSP) personnel, stationed statewide, on a quarterly basis. Every effort is made to collect and record all opioid drug seizures and arrests however, the information provided may not represent the totality of all seizures and opioid arrests made by PSP personnel.
Data is currently available from January 1, 2013 through July 1, 2018.
Seizure
Opioids seized as a result of undercover buys, search warrants, traffic stops and other investigative encounters.
An incident is a Pennsylvania State Police (PSP) recorded violation of the Controlled Substance Act and an entry into the PSP Statistical Narcotics System.
By regulation, entry is made by the PSP as stated in PSP Administrative Regulation 9-6:
When violations of The Controlled Substance, Drug, Device and Cosmetic Act are reported, the required statistical information concerning the incident shall be entered into the Statistical Narcotic Reporting System (SNRS).
Incidents may include undercover buys, search warrants, traffic stops and other investigative encounters
So, an “incident” is not based on any arrest, but on a reported violation, though it often can include arrests.
The incidents that are selected and forwarded to the portal are those that include a record of one or more seizures of the opioid drugs. In turn, a subset of those selected incidents also contains a record of one or more arrests.
This is PSP data only, it would not include any Federal case/incident data.

This dataset contains information on the number of doses given for Naloxone throughout the Commonwealth of Pennsylvania by County. If a (-1) is listed in the county it means Not Recorded, as this field was blank by the Patient Care Report (PCR) vendor or the EMS Provider. Data is updated Quarterly starting with the first Quarter of Calendar Year 2018.

View quarterly trends in overdose rates for Any Drug Overdoses, Any Opioid Overdoses and Heroin Overdoses at the state and county level.
Please see Overdose Data Technical Notes for additional details: https://www.health.pa.gov/topics/Documents/Opioids/OverdoseDataTechnicalNotes.pdf

This dataset reports number of successful naloxone reversals by police officers, as self-reported by municipal police departments, Capitol Police, and Pennsylvania State police. The data is stratified by county and by year. Note that there is no legislation mandating that law enforcement report naloxone reversals to DDAP; these data represent voluntary self-reports from departments.
NA - Not applicable. No FIPS code or county code exist for Pennsylvania State Police and Capitol Police. Also, counties labelled “NA” do not have municipal police departments and are only covered by Pennsylvania State Police.

View quarterly trends in opioid dispensation data for all Schedule II-V opioids.
Please see PDMP Data Technical Notes for additional details: http://www.health.pa.gov/Your-Department-of-Health/Offices%20and%20Bureaus/PaPrescriptionDrugMonitoringProgram/Documents/PDMPDataTechnicalNotes.pdf
More information from U.S. Department of Justice
https://www.deadiversion.usdoj.gov/schedules/
Schedule I Controlled Substances
Substances in this schedule have no currently accepted medical use in the United States, a lack of accepted safety for use under medical supervision, and a high potential for abuse.
Some examples of substances listed in Schedule I are: heroin, lysergic acid diethylamide (LSD), marijuana (cannabis), peyote, methaqualone, and 3,4-methylenedioxymethamphetamine ("Ecstasy").
Schedule II/IIN Controlled Substances (2/2N)
Substances in this schedule have a high potential for abuse which may lead to severe psychological or physical dependence.
Examples of Schedule II narcotics include: hydromorphone (Dilaudid®), methadone (Dolophine®), meperidine (Demerol®), oxycodone (OxyContin®, Percocet®), and fentanyl (Sublimaze®, Duragesic®). Other Schedule II narcotics include: morphine, opium, codeine, and hydrocodone.
Examples of Schedule IIN stimulants include: amphetamine (Dexedrine®, Adderall®), methamphetamine (Desoxyn®), and methylphenidate (Ritalin®).
Other Schedule II substances include: amobarbital, glutethimide, and pentobarbital.
Schedule III/IIIN Controlled Substances (3/3N)
Substances in this schedule have a potential for abuse less than substances in Schedules I or II and abuse may lead to moderate or low physical dependence or high psychological dependence.
Examples of Schedule III narcotics include: products containing not more than 90 milligrams of codeine per dosage unit (Tylenol with Codeine®), and buprenorphine (Suboxone®).
Examples of Schedule IIIN non-narcotics include: benzphetamine (Didrex®), phendimetrazine, ketamine, and anabolic steroids such as Depo®-Testosterone.
Schedule IV Controlled Substances
Substances in this schedule have a low potential for abuse relative to substances in Schedule III.
Examples of Schedule IV substances include: alprazolam (Xanax®), carisoprodol (Soma®), clonazepam (Klonopin®), clorazepate (Tranxene®), diazepam (Valium®), lorazepam (Ativan®), midazolam (Versed®), temazepam (Restoril®), and triazolam (Halcion®).
Schedule V Controlled Substances
Substances in this schedule have a low potential for abuse relative to substances listed in Schedule IV and consist primarily of preparations containing limited quantities of certain narcotics.
Examples of Schedule V substances include: cough preparations containing not more than 200 milligrams of codeine per 100 milliliters or per 100 grams (Robitussin AC®, Phenergan with Codeine®), and ezogabine.

This dataset contains the total counts of Neonatal Abstinence Syndrome (NAS) babies born on to Medical Assistance (MA) by case county. The counts cover calendar years 2015 and 2016.